ストックスクリーナーアプリを入手
27.16
1.31%
0.35
アフターアワーズ：
27.02
-0.14
-0.52%
Pfizer Inc (PFE) 最新ニュース
Pfizer, ASKA Pharma to co-promote RSV vaccine Abrysvo in Japan - BioSpectrum Asia
BMO Maintains Outperform on Pfizer (PFE) March 2026 - Meyka
Pfizer's payout ratio is still over 100%. Is a dividend cut inevitable? - MSN
Pfizer Tries Again In Atopic Dermatitis, This Time With A Trispecific - Citeline News & Insights
Pfizer eczema drug clears Phase 2, sets up a fresh challenge to Dupixent - TechStock²
Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable? - Yahoo Finance
BMO reiterates Pfizer stock Outperform rating on antibody data - Investing.com
Pfizer (PFE) Advances Tilrekimig for Atopic Dermatitis with Posi - GuruFocus
Pfizer reports positive data from Phase 2 study for atopic dermatitis antibody (PFE:NYSE) - Seeking Alpha
Pfizer (PFE) Reports Promising Results from Phase 2 Atopic Derma - GuruFocus
Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study - Yahoo Finance
Pfizer shares dip despite positive trial results for skin condition drug - Investing.com Nigeria
Pfizer’s tilrekimig meets Phase 2 trial endpoint for dermatitis - Investing.com India
Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis - Business Wire
Streptococcus Market Is Going to Boom | AbbVie • Pfizer • Merck & Co. • GlaxoSmithKline - openPR.com
Anti Infective Vaccines Market Witnessing Massive Growth - openPR.com
How Apellis Adding Ex-Pfizer R&D Chief Mikael Dolsten to Its Board Will Impact Apellis (APLS) Investors - simplywall.st
Where Will Eli Lilly Stock Be in 10 Years? - The Motley Fool
Is Pfizer Inc. stock gaining market share2025 Bull vs Bear & Community Consensus Trade Signals - Naître et grandir
American Century Companies Inc. Sells 546,598 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs - BioPharma Dive
Pfizer Obesity Nod In China And Cancer Wins Reframe Long Term Growth - Yahoo Finance
Pfizer Adds New Early-Stage Heart Failure Candidate to Its China Pipeline - TipRanks
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer stock forecast for 2030. $10B obesity bet and BRAFTOVI approval bets $45 upside - Traders Union
Pfizer (PFE) Gains Approval for Obesity Drug in China - GuruFocus
Pfizer's (PFE) GLP-1 Treatment Gains Approval in China - GuruFocus
Orion Porfolio Solutions LLC Cuts Stake in Pfizer Inc. $PFE - MarketBeat
Edgar Lomax Co. VA Cuts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Beddow Capital Management Inc. Sells 62,275 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer's Weight Loss Injection GLP-1 Ecnoglutide Injection Approved in CN - AASTOCKS.com
China Greenlights Pfizer’s Obesity Injection as Generic Rivals Approach - FXLeaders
Pfizer Secures China Nod for Obesity Drug as Generics Loom - Bloomberg
China approves Pfizer GLP-1 drug for weight management - Yahoo Finance
China approves Pfizer GLP-1 drug for weight loss - Reuters
Pfizer Gets OK For $29M SEC Payout From Insider Case - Law360
Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund - Reuters
Pfizer’s Comirnaty Update: What U.S. Patients Need To Know Now - AD HOC NEWS
Pfizer Arbitration Confidentiality Rule Is Lawful, NLRB Says - Law360
Smart Money Is Betting Big In PFE Options - Benzinga
Pfizer Bladder Cancer Trial Results Deepen Oncology Growth And Risk Debate - Yahoo Finance
Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Aerospace Medicine Market is Going to Boom | Major Giants Pfizer, Novartis, Bayer - openPR.com
Retinal Vein Occlusion Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Kodiak Sciences, Roche/Chugai Pharmaceuticals, Novartis, Allergan, Pfizer - Barchart.com
Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations? - TradingView
Pfizer Inc. $PFE Shares Acquired by JT Stratford LLC - MarketBeat
Picton Mahoney Asset Management Acquires Shares of 200,735 Pfizer Inc. $PFE - MarketBeat
Pfizer: Obesity Hype And Vaccine Policy Shocks (NYSE:PFE) - Seeking Alpha
Skeletal Dysplasia Market - GlobeNewswire Inc.
Precision Trading with Pfizer Inc. (PFE) Risk Zones - Stock Traders Daily
Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline - Finviz
Pfizer Arbitration Gag Provision Is Lawful, Labor Board Rules - Bloomberg Law News
Pfizer’s Comirnaty update: what US patients really need now - AD HOC NEWS
Celiac Disease Market: Expanding Revenue Landscape to 2034 – DelveInsight | Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer - StreetInsider
Pfizer's Portfolio Renewal In ProgressHigh Yields For The Patient (NYSE:PFE) - Seeking Alpha
Uterine Fibroid Treatment Drugs Market Is Going to Boom Rapidly | - openPR.com
Yeast Infection Treatment Market Is Going to Boom Rapidly | Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Sanofi S.A. - openPR.com
ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP - The Manila Times
Pfizer Inc. $PFE Shares Sold by Mcdonald Partners LLC - MarketBeat
Griffith & Werner Inc. Makes New Investment in Pfizer Inc. $PFE - MarketBeat
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
Dimensional Fund Advisors LP Acquires 1,579,117 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. (NYSE:PFE) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Pfizer Inc. (PFE) and Astellas Report Positive Phase 3 EV-304 Results for PADCEV Plus Keytruda in Bladder Cancer - Finviz
Pfizer (NYSE:PFE) Shares Down 2.4%Here's Why - MarketBeat
Pfizer Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
2.66%
1.32%
大文字化:
|
ボリューム (24 時間):